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ABSTRACT
Poly(ADP-ribose) polymerase-1 (PARP-1) has
become an important pharmacological target in the
treatment of cancer due to its cellular role as a
`DNA-strand break sensor', which leads in part to
resistance to some existing chemo- and radiological
treatments. Inhibitors have now been developed
which prevent PARP-1 from synthesizing poly(ADP-
ribose) in response to DNA-breaks and potentiate
the cytotoxicity of DNA damaging agents. However,
with the recent discoveries of PARP-2, which has
a similar DNA-damage dependent catalytic activity,
and additional members containing the `PARP cata-
lytic' signature, the isoform selectivity and resultant
pharmacological effects of existing inhibitors are
brought into question. We present here the crystal
structure of the catalytic fragment of murine
PARP-2, at 2.8 AÊ resolution, and compare this to the
catalytic fragment of PARP-1, with an emphasis on
providing a possible framework for rational drug
design in order to develop future isoform-speci®c
inhibitors.
INTRODUCTION
Poly(ADP-ribose) polymerase-2 (PARP-2) (1±3) is one
member of a growing family (18 proteins to date) related by
a highly conserved catalytic fragment (CF) (J.-C.AmeÂ et al.,
submitted), capable of synthesizing polymers of ADP-ribose,
utilizing NAD+ as a substrate. Characterized family members
currently include the proteins PARP-1, PARP-3 (2,4),
Tankyrase 1 (5), Tankyrase 2 (6,7), TiPARP (8) and vPARP
(9). To date, the only proteins of this family known to generate
poly(ADP-ribose) (PAR) as a direct response to DNA breaks
are PARP-1 and -2 (10). These proteins bind directly to single-
strand DNA breaks (PARP-1) or gaps (PARP-1 and -2) and as
such are enzymatically hyper-activated (~500-fold over basal
levels for PARP-1); the ADP-ribose moiety of bound NAD+ is
then transferred to speci®c acceptor proteins, and to PARP-1
and -2 themselves via an auto-modi®cation reaction. With
successive enzymatic rounds, this initial post-translational
modi®cation can be extended to yield long, branched,
polymeric chains of ADP-ribose [reviewed in de Murcia and
Shall (11) and Murkle (12)].
Given that all currently identi®ed PAR acceptors are DNA-
binding proteins, and that PAR itself has considerable
chemical and biophysical similarity to nucleic acids, PAR
covalently attached to a DNA-binding protein could compete
for the DNA-binding site on the modi®ed protein and displace
it from DNA, allowing DNA repair proteins access to the
DNA break. Known polymer acceptors include histones
(mainly H1 and H2B) (13), DNA topoisomerases I and II
(13,14), DNA polymerase b (15), p53 (16) and XRCC1 (17).
Immunoprecipitation and co-puri®cation experiments have
demonstrated that both PARP-1 and PARP-2 are directly
associated with a short-patch base excision repair (BER)
complex, comprising the proteins XRCC1, DNA polymerase
b and DNA Ligase IIIa (10,17±20). Moreover, the importance
of both PARP-1 and -2 in BER and single-strand break repair
(SSBR) has been supported by a wide range of experimental
data; knock-out mice de®cient in either protein, show
hypersensitivity to both alkylating agents and g-irradiation
(both strong inducers of SSBR) (21,22), and repair of
alkylated bases in cell lines derived from these mice, shows
a signi®cant delay or defect (10,23,24). Additional evidence to
support a role for the PARPs in BER and SSBR, arises from
the observation that short oligomeric lengths of ADP-ribose,
attached to PARP-1 or -2, are necessary for either the
recruitment or enhanced binding of BER/SSBR associated
protein partners, principally XRCC1 (10,17,20,25). Further-
more, in living cells, PAR production in the vicinity of
localized DNA strand breaks has recently been shown to be
essential for the rapid recruitment of XRCC1 to the damage
sites [Okano et al. (26) and J.-C.AmeÂ et al., submitted].
Because it is implicated in the resolution of DNA breaks,
PARP-1 has attracted a great deal of attention as a therapeutic
drug target in the treatment of cancer. A number of method-
ologies have been proposed; including the use of PARP-1
inhibitors to obstruct DNA repair, thus increasing the
cytotoxicity of certain anticancer agents (both in chemo- and
radiotherapies) (27,28). It has also been selected as a target for
medical conditions involving oxidant-mediated cell death,
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such as ischaemia-reperfusion injuries, neurodegenerative
disorders and endotoxic shock, due to its involvement in
other cellular pathways that are not discussed here [reviewed
in (29,30)].
Until relatively recently, PARP-1 was believed to be
responsible for all the DNA-damage dependent PAR synthesis
in mammalian cells. However, a second DNA-damage
dependent activity, PARP-2, was subsequently identi®ed (1).
Like PARP-1, PARP-2 interacts with components of the BER
and single-strand gap-repair pathways, and can probably
function as both a homo- and heterodimer with PARP-1 (10).
PARP-2 lacks the N-terminal tandem zinc ®ngers and BRCT
domain of PARP-1, which are replaced by a small highly basic
N-terminal DNA-binding domain, with the E domain acting
both as a dimerization and automodi®cation domain (10), but
shares the C-terminal catalytic domain, which is the unifying
feature of the wider PARP family (Fig. 1). The identi®cation
of 18 PARPs in mammalian cells potentially complicates the
development of inhibitors intended to achieve targeted
pharmacological effects. With this in mind, we have now
determined the crystal structure of the catalytic fragment of
murine PARP-2 (PARP-2-CF) at 2.8 AÊ resolution.
Comparison with the known structure of chicken PARP-1-
CF provides a rational framework for the future development
of type-speci®c PARP inhibitors.
MATERIALS AND METHODS
Expression and puri®cation
Full-length recombinant murine PARP-2 (PARP-2-FL) was
expressed in insect cells (Spodoptera frugiperda, Sf9). The
baculovirus encoding the full-length protein, was generated as
described previously (1). Insect cells were cultured in shaker
¯asks, containing SF900II media (supplemented with penicil-
lin and streptomycin), with growth conditions of 27°C and
150 r.p.m., as per the manufacturer's instructions (Life
Technologies). Virus was ampli®ed from cells infected at a
cell density of 2.0 3 106 cells/ml, a multiplicity of infection
(MOI) of 0.1, and a 3-day incubation period. For expression,
Sf9 cells were infected at the same cell density, but with an
MOI of 2, and a 3-day incubation period. Cells were harvested
by centrifugation at 1000 g for 5 min, and the resulting cell
pellet stored at ±80°C until required.
The cell pellet resulting from 1.25 l of expression culture
was resuspended, on ice, in 45 ml of PBS A; 171 mM NaCl,
10.6 mM KH2PO4, 3.35 mM KCl, 1.76 mM Na2HPO4,
pH 7.2, supplemented with protease inhibitors. Cells were
lysed through a combination of the thawing process, hand-
homogenization and a brief sonication step. Cell debris was
then removed by high-speed centrifugation at 40 000 g for
45 min. The resulting supernatant was additionally clari®ed by
the addition of protamine sulphate to a ®nal concentration
of 1 mg/ml. Precipitated material was again removed by
high-speed centrifugation.
Heparin Sepharose 6 resin (Pharmacia) was added to the
clari®ed supernatant and incubated, with mixing, at 4°C for
30 min (~16 ml resin per 45 ml cell extract). The resin slurry
was then distributed between a number of disposable plastic
chromatography columns, and washed with successive
volumes of PBS A + 100 mM NaCl. Partially puri®ed protein
was eluted with PBS A + 450 mM NaCl. Fractions containing
PARP-2-FL were identi®ed and pooled, then diluted ~6-fold
with the addition of 100 mM Tris±HCl pH 7.5, 1 mM DTT,
0.5 mM EDTA (to reduce the overall NaCl concentration to
~100 mM). This was then applied to an ECH-Sepharose 4B
(Pharmacia)/3-aminobenzamide coupled af®nity column. The
column was washed with a linear salt gradient from 0.1 to 1 M
NaCl in 100 mM Tris±HCl pH 7.5, 1 mM DTT, 0.5 mM
EDTA, and bound protein eluted with 100 mM Tris±HCl,
400 mM NaCl, 3 mM 3-methoxybenzamide, 1 mM DTT,
0.5 mM EDTA. The protein was buffer exchanged into 10 mM
Tris±HCl pH 8.0, 100 mM NaCl, and concentrated to 24 mg/ml
using Vivaspin 500 concentrators (10 kDa cut-off). Puri®ed
PARP-2-FL was stored at 4°C.
Crystallization and data collection
Crystallization trials were carried out at 24 mg/ml in hanging-
drop experiments using Structure Screen I (MDL). Small
Figure 1. Schematic representation of the functional domains of chicken PARP-1 and mouse PARP-2. The grey box indicates the crystallized region of
PARP-2 and compares it to the previous crystal structure of chicken PARP-1 (PARP-1-CF, PDB: 2PAW). Protein domains (A±F) are labelled according to
de Murcia and Shall (11). DBD = DNA binding domain; NLS = nuclear localization sequence; BRCT = BRCA1 C-terminus.
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orthorhombic crystals were observed in condition 38. This
condition was optimized, again in hanging-drop experiments,
to mixing 1 ml of protein (24 mg/ml in 10 mM Tris±HCl
pH 8.0, 100 mM NaCl) with 1 ml of precipitant containing 9%
PEG 8000, and 100 mM Tris±HCl pH 7.5. Data to 2.8 AÊ were
collected from a single crystal at 100 K at the SRS, Grenoble,
and recorded on an ACSD scanner. Images were integrated
using MOSFLM (31) and reduced/scaled using programs
of the CCP4 suite (32). The protein crystallized in space-group
P212121 with cell dimensions of a = 83.65 AÊ , b= 85.82 AÊ
and c = 139.46 AÊ . Statistics for the data collection are given in
Table 1.
Analysis of crystal content
Calculations of crystal volume were not commensurate with
integral numbers of the full-length protein in the asymmetric
unit, so that direct analysis of crystal content was required.
Several crystals (»30) were harvested from a crystallization
drop, and washed in successive volumes of Ultra-pure water.
After washing, crystals were pooled, then dissolved in 10 mM
Tris±HCl pH 7.5, 100 mM NaCl, 1 mM EDTA, 1 mM DTT
and analysed on a 12.5% SDS±PAGE gel. Crystallized
material corresponded to a polypeptide migrating with an
apparent molecular mass of »50 kDa, indicating that a
proteolytic or break-down product had crystallized, rather
than the full-length protein. N-terminal sequencing and mass-
spectrometry con®rmed the crystalline protein as a C-terminal
fragment (residues 209±557). On the basis of this, the
asymmetric unit was expected to contain two molecules
with a solvent content of 61% (v/v).
Structure determination and re®nement
The structure of the crystallized fragment of murine PARP-2
was determined by molecular replacement using AMoRe (33).
The structure of the catalytic domain from chicken PARP-1
was used as a search model (PDB: 2PAW), but with the amino
acid sequence of PARP-2 threaded onto the PARP-1 fold. Two
solutions were obtained, and improved by rigid body re®ne-
ment and subsequent simulated annealing in CNS (34).
Difference maps were used to rebuild the initial model in O
(35). Iterative cycles of re®nement and manual intervention
gave the current model which consists of 5461 protein atoms
and 96 solvent atoms, with R = 0.244 and Rfree = 0.268 for
»5% of the data omitted from re®nement. NCS restraints were
throughout re®nement, with the exclusion of amino acid
groups 207±215, 235±250, 290±296, 320±335, 343±357 and
Table 1. Crystallographic statistics
Data collection All data (outer shell)
Rmerge 0.073 (0.255)
I/s(I) 4.2 (2.4)
Completeness (%) 99.9 (99.9)
Multiplicity 4.0 (4.1)
No. of unique re¯ections 25 407
Structure re®nement
No. of atoms (protein) 5461
No. of atoms (All) 5558
Resolution range (AÊ ) 29.95±2.8
Rcryst 0.244
Rfree 0.268
Figure 2. Structure of the CF of murine PARP-2. (a) Stereo-pair secondary structure cartoon of PARP-2-CF coloured blue to red from the visible N-terminus
at residue 207 to the visible C-terminus at residue 557. The disordered loop comprising residues 325±331 is represented as a dotted line. (b) As (a), but
rotated 90° around the horizontal axis.
458 Nucleic Acids Research, 2004, Vol. 32, No. 2
 at U






374±380, which showed deviations in conformation between
the two crystallographically independent molecules. The
r.m.s. deviation for all Ca atoms between the two molecules
is 0.124 AÊ . Coordinates have been deposited in the Protein
Databank (code: 1GS0). Crystallographic statistics are given
in Table 1.
RESULTS
Full-length murine PARP-2 was expressed in insect cells and
puri®ed to homogeneity (see Materials and Methods). In
crystallization trials, crystals took extended periods of time to
appear, in some cases up to 6 months from the date of
experimental set-up. Despite full-length protein being used,
slow proteolysis during the time course of the experiment
produced a stable fragment of »50 kDa (as judged by SDS±
PAGE analysis) which crystallized.
N-terminal sequencing and western blots identi®ed the
crystalline protein as a C-terminal fragment (residues
194±559) encapsulating the catalytic function of the protein,
but lacking the putative 7 kDa DNA-binding domain and
16 kDa dimerization domains. The structure of this PARP-2
catalytic fragment (PARP-2-CF) was determined by
molecular replacement with the structure of chicken PARP-
1-CF (PDB: 2PAW), and re®ned at 2.8 AÊ (see Materials and
Methods). Two molecules of PARP-2-CF are present in
the asymmetric unit of the crystal. Clear electron density
corresponding to residues 209±557 of the full-length protein
can be seen for both molecules, apart from the loops
comprised of residues 325±330 which appear to be poorly
ordered in these crystals.
PARP-2-CF structure
The PARP-2-CF structure consists of two main parts: an
a-helical N-terminal domain comprising residues 207±324,
and a mixed a/b C-terminal domain (residues 332±557)
containing the catalytic glutamate residue (Glu534) (Fig. 2).
As expected, the overall fold of PARP-2-CF is very similar to
that of PARP-1-CF (36), with an r.m.s. deviation of 1.16 AÊ
between 339 common Ca positions when the structures are
superimposed (37) (Figs 3 and 5a).
Figure 3. Secondary structure-based sequence alignment between PARP-2-CF and PARP-1-CF. A sequence alignment for PARP-2-CF and PARP-1-CF is
shown, shaded to detail both identical residues (black) and conserved residues (grey) between the two molecules. Secondary structure elements are also
shown, labelled according to Ruf et al. (36). Amino acid residues important for catalytic function are also highlighted.
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The majority of secondary structure elements are com-
pletely conserved between the two CFs; all a-helix, b-sheet
and 310 helix motifs found in PARP-1-CF are also present in
PARP-2-CF, with the notable exception of b-strand l which is
absent from the PARP-2-CF structure due to a structural
rearrangement as a result of a three-residue insertion after
b-strand k (Fig. 3). An additional 310 helix (residues 481±483)
is also found in PARP-2-CF, forming part of the loop
connecting b-strands f and g.
Catalytic mechanism of PARP
PARP-1 is a target of substantial pharmaceutical interest (38),
and a number of crystal structures of PARP-1-CF in complex
with inhibitors have been reported. Although structures of
Figure 4. Mechanism of poly-ADP-ribosylation by PARP-1 and PARP-2. PARP-1 and PARP-2 catalyse the transfer of the ADP-ribose moiety of NAD+ to a
nucleophilic acceptor. In an initiation reaction, the acceptor is the carboxyl side chain of a glutamate residue on the acceptor protein, but is the 2¢ hydroxyl
of the adenine or nicotinamide ribose of the poly-ADP-ribose in elongation and branching reactions, respectively. A = adenine-ribose; P = phosphate;
N = nicotinamide-ribose, and NIC = nicotinamide.
Figure 5. Amino acid residues shown both in parentheses and underlined are in PARP-1. All other residues are in PARP-2. In addition, cartoon
representations of PARP-1 are coloured yellow, and those of PARP-2 coloured grey. The catalytic residue E534 (E988 in PARP-1) is highlighted in green, in
all cases. (a) Superimposed Ca traces of PARP-1-CF and PARP-2-CF. Stereo-pair diagram showing superimposed Ca backbone traces for PARP-1-CF
(PDB: 2PAW) and PARP-2-CF. Also shown are stick representations of the ADP-ribose moiety of carba-NAD (shown in magenta) and NAD+ (cyan). The
positions of carba-NAD and NAD+ were modelled by comparisons with the ligand-bound crystal structures of PARP-1 (PDB: 1A26), and diphtheria toxin
(PDB: 1TOX), respectively. (b) Polymer acceptor site. The ADP-ribose moiety of NAD+ (coloured magenta) is shown bound to the donor site of PARP-1
(PDB: 1EFY), along with a superimposition of the equivalent secondary structure elements in PARP-2. All residues involved in coordinating the substrate are
highly conserved between the two PARP molecules. The extended loop unique to PARP-2 is clearly visible, consisting of residues Leu523±Thr529. In
particular, residue Tyr528 is presented towards the acceptor site, possibly providing additional interactions with the pyrophosphate backbone of the bound
substrate. (c) Polymer donor site. A model for NAD+ (shown in cyan) bound to the donor site of PARP-2 is shown. All residues involved in coordination of
the substrate are again strongly conserved between PARP-1 and PARP-2, apart from residue Gln763, which is replaced by Lys308 in PARP-2. (d) Helix F in
PARP-2 is displaced towards the donor site. In comparison to PARP-1, the top of helix F in PARP-2 is displaced towards the donor site of the molecule. This
is due to the replacement of the side-chain of Tyr575 in PARP-1, normally buried in a hydrophobic pocket, with the solvent-exposed residue Glu302 in
PARP-2. (e) PARP inhibitors bound to the donor site. PARP inhibitors (for which the structures of complexes with PARP-1 are available) are shown bound to
the donor site of PARP-2. Superimposition of topologically equivalent residues, between PARP-1 and PARP-2, facilitated the modelling of these inhibitors.
The inhibitor 2-(3¢-methoxyphenyl) benzimidazole-4-carboxamide (BZC) is highlighted (shown in pink), demonstrating the proximity of helix F and hence
residues Ser304 and Lys308 to the donor site, providing possible targets for future PARP-2 selective/discriminative inhibitors. The inhibitors shown are:
3,4-dihydro-5-methyl-isoquinolinone (DHQ, PDB: 1PAX), 4-amino-1,8-naphthalimide (4AN, PDB: 2PAX), 3-methoxybenzamide (3 MB, PDB: 3PAX) and
BZC (PDB: 1EFY).
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PARP-2 in complex with inhibitors are not yet available, the
overall similarity of the PARP-1 and PARP-2 CFs allows a
detailed comparison between the ligand binding sites, which
will have excellent predictive power for the future design of
isoform-speci®c PARP inhibitors.
PARP-1 and PARP-2 are able to catalyze three related but
distinct reactions in which the ADP-ribose moiety of NAD+ is
transferred to one of three different acceptor groups, which in
ordered combination generate PAR-modi®ed proteins.
`Initiation' involves transfer to the carboxylate group of a
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glutamic acid side chain on the modi®ed protein, while
subsequent `elongation' and `branching' reactions transfer
ADP-ribose to the 2¢-hydroxyl of the adenine or nicotinamide
ribose of an already attached ADP-ribose chain. The sequen-
tial nature of the reaction therefore requires adjacent binding
sites for the `acceptor' terminal ADP-ribose of the existing
poly- or oligo-ADP-ribose chain, and for the `donor' NAD+
ligand that will provide the ADP-ribose to be added (Fig. 4).
PARP-2 acceptor site
To analyse interactions in the PARP-2 acceptor site, we
modelled ADP into the crystal structure of PARP-2-CF by
superimposing the crystal structure of the PARP-1-CF com-
plex with carba-NAD (PDB: 1A26), as it has been demon-
strated previously that the ADP moiety of this ligand
delineates the binding site of a poly(ADP-ribose) acceptor
molecule (39). All amino acid residues involved in the
coordination of the ADP-moiety are conserved in PARP-2-CF,
both in their identity and in their spatial arrangement (Fig. 5b).
The pyrophosphate backbone can be bound through the
formation of hydrogen bonds to the Ne2 atom of His370 (826:
numbers in brackets indicate the topologically equivalent
residue in PARP-1), the z-amino group of Lys445 (903) and
the backbone amides of residues 531 and 532 (985 and 986).
In addition, the hydroxyl groups of the ribose sugar can
hydrogen-bond to Tyr449 (907) and to the catalytic residue
Glu534 (988), with the adenine moiety packed against the
side-chain of Met432 (890).
The local environment of the acceptor site in PARP-2-CF is
modi®ed compared to PARP-1 however, due to a three-amino
acid insertion in the loop connecting b-strands k and l (Figs 3
and 5a). Comparison of this loop in the two PARP structures
identi®es PARP-2 residues Leu523 and Leu530 as topologi-
cally equivalent to residues Asn980 and Leu984 of PARP-1,
but with the additional PARP-2 residues 524-Asn-Pro-Glu-
Gly-Tyr-Thr-530 forming a six-residue excursion from the
backbone path observed in PARP-1-CF (Fig. 5b). Within the
longer PARP-2 loop, the side chain phenyl of Tyr528 (which
has no equivalent in PARP-1) points directly into the acceptor
site, with the hydroxyl group in a position to hydrogen-bond to
the Nd2 of Asn531 and/or to interact with the pyrophosphate
backbone of bound PAR. Although the loop is well-ordered in
the crystals, it has different conformations in the two
crystallographically independent molecules in the crystal
structure, with the peptide bond preceding Pro525 in a trans
conformation in one and cis in the other. As well as providing
the binding site for the terminal ADP-ribose of an existing
chain in elongation and branching reactions, this site must also
furnish interactions to position the glutamate and adjacent
polypeptide chain of a protein acceptor in the initiation
reaction. The nature of these interactions, which may afford
some degree of protein substrate speci®city for ADP-
ribosylation, are unknown in both PARP-1 and -2.
PARP-2 donor site
In the absence of an experimental structure for NAD+ bound to
PARP-1 or PARP-2, we have modelled the binding of NAD+
in the donor site of the PARP-2-CF molecule, on the basis of
the structure of the NAD+-bound diphtheria toxin (a mono-
ADP-ribosyltransferase) (PDB: 1TOX) (40) as previously
described for PARP-1 (41). As with the acceptor site, most of
the residues involved in coordinating NAD+ within the donor
site are conserved in PARP-1 and PARP-2 (Fig. 5c) (41). The
2¢ hydroxyl residue of the donor ribose group makes a
hydrogen bond with the side-chain carboxyl of the catalytic
residue Glu534 (988). This interaction positions the C1¢N for
nucleophilic attack by the 2¢ hydroxyl of the acceptor ribose
group. Additional conserved hydrogen bonding interactions
serve to position the donor NAD+ molecule: the backbone
oxygen of Gly418 (876) to N6A, Asp315-Od2 (770) to N7A,
the backbone nitrogen of Arg420 (878) to N1A, Ser406-Og
(864) to O2¢A, the backbone oxygen of Gly405 (863) to N7N,
the backbone nitrogen of Gly405 to O7N, Ser446-Og (904) to
O7N, and Tyr449-OH (907) to O4¢N. The only difference
between PARP-1 and PARP-2 in donor site interactions, is the
replacement of Gln763 in PARP-1, with a lysine (308) in
PARP-2. Gln763 hydrogen bonds to the pyrophosphate moiety
of the donor site NAD+ via its side-chain amide group, but this
interaction could be fully recapitulated by the Ne of Lys308.
PARP inhibitor interactions
A large number of PARP-1 enzymatic inhibitors have been
developed, the majority of which mimic to some degree the
nicotinamide moiety of NAD+ and bind to the donor site of the
protein. The residues in the donor site of PARP-1 that provide
hydrogen-bonding interactions with these inhibitors, are
completely conserved in PARP-2. Hydrogen bonds can be
formed between Gly405-N (863), Gly405-O (863) and
Ser446-Og (904) and an inhibitor's amide or lactame group
with additional, non-polar interactions with Tyr438 (896) and/
or Tyr449 (907). Additional inhibitor speci®city has been
correlated with the formation of additional hydrogen bonds
either to the catalytic glutamate, Glu534 (988), or to the
hydroxyl group of Tyr449 (907). Superimposition of known
PARP-1/inhibitor complexes [PDB: 1EFY, 1PAX, 2PAX,
3PAX and 4PAX; (41,42)] onto the PARP-2-CF structure,
shows that the binding environment in both PARPs is virtually
identical, suggesting that these existing PARP-1 inhibitors
would show little discrimination between PARP-1 and PARP-
2 (Fig. 5e). However, the position of 2-(3¢-methoxyphenyl)
benzimidazole-4-carboxamide (BZC; PDB: 1EFY) within the
donor site suggests that selectivity for (or against) PARP-2
inhibition could be introduced by inhibitor groups designed to
interact with the positively charged terminal amino group of
Lys308, which replaces the polar side chain of Gln763 found
at this position in PARP-1. A second possible source of
selectivity results from the displacement in PARP-2, relative
to PARP1, of the top of helix F towards the catalytic site. In all
the currently available PARP-1 structures (both in the
presence or absence of bound inhibitors/substrates), helix F
is presented in the same conformationÐwith no movement of
the helix either towards or away from the catalytic site.
However, this helix is displaced in PARP-2 due to the
replacement of the buried side-chain of Tyr757 in PARP-1, by
the exposed side-chain of Glu302 in PARP-2, which presents
the side-chain hydroxyl of Ser304 towards the donor site
(Fig. 5d). Additional iso-form speci®city could also be
introduced by production of inhibitors that could simultan-
eously occupy both the donor and acceptor sites of the protein,
providing hydrogen-bonding access to Tyr528; the most
apparent difference between the two CFs.
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Of the 18 PARP activities identi®ed in mammalian cells so far,
only PARP-1 and PARP-2 are activated by the presence of
interruptions in the DNA, and thereby are implicated in DNA
damage repair. Consistent with this, both PARP-1 and -2
interact with the enzymes involved in small-patch gap repair
(DNA polymerase b and DNA ligase III) and the associated
XRCC1 scaffold protein (10). In addition, PARP-1 and -2 can
both homo- and heterodimerize in vitro and reciprocally trans-
ADP-ribosylate each other, suggesting that they may function
as a unit in vivo (43). PARP-1 and PARP-2 may have
redundant functions which are nonetheless essential for
viability, as mice embryos homozygously defective in both
genes (PARP-1 ±/±, PARP-2 ±/±) die with the onset of
gastrulation (43).
The overall three-dimensional structure of the CF of PARP-
2 is very similar to that of PARP-1, but with some differences
in the vicinity of the acceptor site, which could re¯ect
differences in the substrate proteins ADP-ribosylated by the
two enzymes, and may ultimately provide the means for
engineering differential speci®city into PARP-inhibitors
targeted at DNA repair pathways. Development of isoform-
speci®c inhibitors would also provide a method for dissecting
and elucidating the precise cellular roles for each PARP
protein. Some putative PARP-2 selective inhibitors have
already been identi®ed in yeast-growth inhibition studies (44),
but co-crystal structures would be necessary to provide the
necessary details of the drug±protein interactions.
The most signi®cant structural difference between the two
enzymes occurs N-terminal of the common `E' domain and
CF, where the large zinc ®nger DNA-binding domain (DBD)
is replaced by a highly basic 64-residue DBD in PARP-2.
Although able to bind DNA in isolation from the rest of the
protein, the PARP-2-DBD does not have a folded structure in
solution, indicated by Circular Dichroism and 1D-NMR
spectroscopy experiments which both showed spectra charac-
teristic of an unstructured polypeptide (our unpublished
observations). The structural nature of the interaction of
PARP-1 and PARP-2 DBDs with DNA has yet to be de®ned.
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